论文部分内容阅读
目的：探讨血管紧张素转化酶抑制剂在冠心病患者临床治疗中的应用价值。方法：随机选取2014年 l 月至2015年5月至我院进行疾病诊疗的冠心病患者82例纳入本次实验研究,对所有患者实施计算机随机分组,分为对照组与观察组,每组患者各占据41例。对照组患者给予一般治疗方案,观察组患者则加用血管紧张素转化酶抑制剂进行临床干预,分析两组的治疗效果。结果：观察组临床总有效率显著高于对照组,P<0.05；观察组复发率显著低于对照组,P <0.05。结论：对冠心病患者在常规治疗的同时联合血管紧张素转化酶抑制剂进行治疗能取得良好的效果,可有效改善患者的临床症状,且临床复发率较低,值得推广。“,”Objective: To investigate the clinical value of angiotensin converting enzyme inhibitor (ACEI) in the treatment of coronary heart disease. Methods:Eighty-two patients with coronary heart disease who were admitted to our hospital from January 2014 to May 2015 were randomly divided into control group and observation group. Al the patients were randomly divided into control group and observation group. Each occupies 41 cases. The patients in the control group were treated with the general treatment regimen. The patients in the observation group were treated with angiotensin converting enzyme inhibitor for clinical intervention, and the therapeutic effect of the two groups was analyzed. Results: The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). The relapse rate in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: The combination of angiotensin converting enzyme inhibitor and conventional therapy can achieve good results in patients with coronary heart disease. It can improve the clinical symptoms of patients with coronary heart disease, and the clinical recurrence rate is low.